PD-1/PD-L1 and CTLA-4 monoclonal antibodies: gastrointestinal toxicity and treatment
10.3760/cma.j.issn.0254-5101.2019.10.012
- VernacularTitle: PD-1/PD-L1和CTLA-4单抗的胃肠道毒性发生与处理
- Author:
Yue FEI
1
;
Xiubao REN
1
;
Xianhuo WANG
1
;
Huilai ZHANG
1
Author Information
1. Department of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma Diagnosis and Treatment, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China
- Publication Type:Review
- Keywords:
Immune checkpoint inhibitor;
Gastrointestinal toxicity
- From:Chinese Journal of Microbiology and Immunology
2019;39(10):794-799
- CountryChina
- Language:Chinese
-
Abstract:
PD-1/PD-L1 (programmed cell death 1/programmed cell death 1 ligand 1) and CTLA-4 (cytotoxic T lymphocyte antigen 4) are currently approved major immune checkpoints. Immune checkpoint inhibitors against them are novel monoclonal antibodies that perform well in a variety of malignancies such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma and Hodgkin′s lymphoma. However, with the increasing use of immune checkpoint inhibitors, immune-related adverse events cannot be ignored. The incidence of gastrointestinal toxicity is second only to skin toxicity. In this review, we focused on the mechanisms of these immune checkpoint inhibitors and the characteristics of gastrointestinal toxicity induced by them, and also discussed the clinical management strategies.
